Research & Development
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial
23 May 2022 -

Japan-based Astellas Pharma Inc. (TSE: 4503) confirmed on Friday the US District Court for the District of Delaware ruling that all asserted claims of the 8,106,183+ADs- 8,524,883+ADs- and RE47301 patents for LEXISCAN(R) (regadenoson injection) 0.4mg/mL are not infringed.

The patent infringement trial involved one Abbreviated New Drug Application (ANDA) filer, US-based pharmaceutical and medical device company Hospira, Inc. According to Astellas, Hospira is requesting permission from the US Food and Drug Administration (FDA) to manufacture and commercialise a generic LEXISCAN(R) product before expiration of the LEXISCAN(R) patents. Astellas said that it plans to appeal the decision and to take legal action to prevent Hospira from launching generic LEXISCAN(R) pending resolution of the appeal.

Astellas said that it is reviewing the potential financial impacts of this district court decision for the fiscal year ending 31 March 2023.

Login
Username:

Password:


Related Headlines

Anebulo Pharmaceuticals reports ANEB-001's positive topline data in Phase 2 clinical trial for acute cannabinoid intoxication

Receptor Life Sciences Announces First Patient Dosed with RLS103 in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of Zylonta in Combination with Other Anti-cancer Agents

Phanes Therapeutics' PT886 receives US FDA orphan drug designation for pancreatic cancer treatment

Pfizer Submits New Drug Application to the US FDA for COVID-19 Treatment Paxlovid

PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 in IPF and Advances LYT-200

Pfizer, BioNTech Ink New Agreement with US government to Provide Additional Doses of COVID-19 Vaccine

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the US government in Ongoing Effort to Provide COVID-19 Treatment Options

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bladder Cancer

Pfizer seeks full FDA approval of Paxlovid

EVERSANA collaborates with Accord BioPharma to support launch of CAMCEVI (leuprolide) 42mg injection emulsion

Ascentage Pharma's APG-5918 receives approval from FDA for first-in-human study

SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments

First Two Patients Dosed in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

US FDA Approves Prestige Biopharma's IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510